📊 WGRX Key Takeaways
Is Wellgistics Health, Inc. (WGRX) a Good Investment?
Wellgistics is in severe financial distress with negative stockholders' equity (-$12.4M), negative gross margins (-27.5%), and critically low cash reserves ($42.6K). The company is burning cash operationally while generating massive losses, suggesting insolvency risk and inability to sustain operations without immediate capital infusion or restructuring.
Why Buy Wellgistics Health, Inc. Stock? WGRX Key Strengths
- Revenue growing 28.7% YoY demonstrating market demand
- Operating in healthcare/pharmaceutical distribution sector with structural demand
- Asset base of $30.5M provides some liquidation value
WGRX Stock Risks: Wellgistics Health, Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency
- Negative gross margin (-27.5%) means losing money on every sale
- Critically low cash position ($42.6K) insufficient for operations
- Severe liquidity crisis with current ratio of 0.09x
- Operating cash flow negative (-$10.9M) indicating ongoing burn
- Net losses deteriorating sharply (-1,377% YoY decline)
- Long-term debt of $23.5M against minimal cash and negative equity
Key Metrics to Watch
- Gross margin trend - must return to positive
- Cash balance and runway - critical survival metric
- Operating cash flow - must turn positive
- Stockholders' equity - path to positive required
- Ability to raise capital or complete strategic alternatives
Wellgistics Health, Inc. (WGRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
WGRX Profit Margin, ROE & Profitability Analysis
WGRX vs Market Sector: How Wellgistics Health, Inc. Compares
How Wellgistics Health, Inc. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Wellgistics Health, Inc. Stock Overvalued? WGRX Valuation Analysis 2026
Based on fundamental analysis, Wellgistics Health, Inc. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Wellgistics Health, Inc. Balance Sheet: WGRX Debt, Cash & Liquidity
WGRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Wellgistics Health, Inc.'s revenue has grown significantly by 29% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
WGRX Revenue Growth, EPS Growth & YoY Performance
WGRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0M | -$83.1K | $-0.04 |
| Q2 2025 | $44.5K | -$83.1K | $-0.01 |
| Q1 2025 | $10.9M | -$83.1K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Wellgistics Health, Inc. Dividends, Buybacks & Capital Allocation
WGRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Wellgistics Health, Inc. (CIK: 0002030763)
📋 Recent SEC Filings
❓ Frequently Asked Questions about WGRX
What is the AI rating for WGRX?
Wellgistics Health, Inc. (WGRX) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.
What are WGRX's key strengths?
Claude: Revenue growing 28.7% YoY demonstrating market demand. Operating in healthcare/pharmaceutical distribution sector with structural demand.
What are the risks of investing in WGRX?
Claude: Negative stockholders' equity indicates technical insolvency. Negative gross margin (-27.5%) means losing money on every sale.
What is WGRX's revenue and growth?
Wellgistics Health, Inc. reported revenue of $23.3M.
Does WGRX pay dividends?
Wellgistics Health, Inc. does not currently pay dividends.
Where can I find WGRX SEC filings?
Official SEC filings for Wellgistics Health, Inc. (CIK: 0002030763) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is WGRX's EPS?
Wellgistics Health, Inc. has a diluted EPS of $-1.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is WGRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Wellgistics Health, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is WGRX stock overvalued or undervalued?
Valuation metrics for WGRX: ROE of N/A (sector avg: 15%), net margin of -433.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy WGRX stock in 2026?
Our dual AI analysis gives Wellgistics Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is WGRX's free cash flow?
Wellgistics Health, Inc.'s operating cash flow is $-10.9M, with capital expenditures of N/A. FCF margin is -46.5%.
How does WGRX compare to other Market stocks?
Vs Default sector averages: Net margin -433.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.09 (avg: 1.8).